Dr. Caesar K. Tin-u, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 268
Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license K8526 (first issued 1999; active) -
Hematology & Oncology Physician
TX license K8526 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Memorial Hermann Sugar Land Hospital Sugar Land, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 268
- Services billed
- 47,973
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 7,500 | 20 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,900 | 32 |
| Injection, dexamethasone sodium phosphate, 1 mg | 890 | 26 |
| Injection, palonosetron hcl, 25 mcg | 570 | 25 |
| Injection, granisetron hydrochloride, 100 mcg | 500 | 15 |
| Insertion of needle into vein for collection of blood sample | 326 | 83 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 317 | 89 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 151 | 36 |
| Administration of chemotherapy into vein, 1 hour or less | 138 | 45 |
| Established patient office or other outpatient visit, 20-29 minutes | 125 | 50 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Sugar Land, TX | 61 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Sugar Land, TX | 54 |
| Xarelto (rivaroxaban) Other prescribers in Sugar Land, TX | 49 |
| Revlimid (lenalidomide) | 32 |
| Enoxaparin Sodium Other prescribers in Sugar Land, TX | 27 |
| Dexamethasone Other prescribers in Sugar Land, TX | 19 |
| Ondansetron Odt (ondansetron) Other prescribers in Sugar Land, TX | 17 |
| Pantoprazole Sodium Other prescribers in Sugar Land, TX | 13 |
| Iclusig (ponatinib hcl) | 12 |
| Pomalyst (pomalidomide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 30 payments worth $843 in total to this clinician.
| Janssen Biotech, Inc. | $221 |
|---|---|
| Daiichi Sankyo Inc. | $179 |
| Novartis Pharmaceuticals Corporation | $82.81 |
| AstraZeneca Pharmaceuticals LP | $55.90 |
| Celgene Corporation | $55.51 |
| Stemline Therapeutics Inc. | $49.50 |
| Taiho Oncology, Inc. | $41.48 |
| Merck Sharp & Dohme LLC | $34.18 |
| Food and Beverage | $843 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $297,161 in research payments for these studies, mostly to the institutions running them.
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732 - A phase 3, randomized, double-blind, placebo-controlled, multicenter s
GlaxoSmithKline, LLC. - A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable kras G12C…
Eli Lilly and Company - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.